TABLE 3.

Comparison of clearance of antigenemia and antigenuria in patients with AIDS and histoplasmosis treated with itraconazole versus fluconazole^a

Treatment	No. of median antigen units (range) in:
	Serum, wk 0	Serum, wk 4	Serum, wk 0	Serum, wk 12	Urine, wk 0	Urine, wk 4	Urine, wk 0	Urine, wk 12
Itraconazole	4.3 (1.2–19.5) (n = 10)	1.5 (0.6–16.2)	10.3 (1.0–19.1) (n = 33)	1.5 (0.5–16.3)	9.2 (1.5–17.5) (n = 21)	7.4 (1.4–16.5)	11.9 (1.3–17.3) (n = 42)	5.2 (0.7–15.7)
Fluconazole	9.1 (1.3–17.5) (n = 35)	4.6 (1.0–18.3)	11.3 (1.2–21.2) (n = 41)	2.0 (0.5–19.1)	11.3 (1.4–17.4) (n = 41)	11.0 (1.3–15.7)	12.3 (1.3–8.3) (n = 44)	6.9 (0.8–15.4)

^aThe analysis is restricted to patients with positive results at baseline that had follow-up specimens after 4 or 12 weeks of therapy. n = the number of patients included in the analysis. The difference in the numbers of patients and median (range) results for week 0 for the comparisons of weeks 0 and 4 and of weeks 0 and 12 is because not all patients had specimens for both analyses, which were conducted at separate times. Furthermore, these baseline results and numbers of patients differ from those in Table 1, which included all subjects who participated in the studies, not only those who could be evaluated for antigen and blood culture clearance.